Patents by Inventor Johannes Laurenz Kellenberger
Johannes Laurenz Kellenberger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10221206Abstract: The application relates to the macrolide compound of the formula (I): wherein * indicates a stereocentre which is in (R) or (S) configuration, or a pharmaceutically acceptable salt or ester thereof.Type: GrantFiled: August 3, 2017Date of Patent: March 5, 2019Assignee: Basilea Pharmaceutica AGInventors: Johannes Laurenz Kellenberger, Jürg Dreier
-
Publication number: 20170327525Abstract: The application relates to the macrolide compound of the formula (I): wherein * indicates a stereocentre which is in (R) or (S) configuration, or a pharmaceutically acceptable salt or ester thereof.Type: ApplicationFiled: August 3, 2017Publication date: November 16, 2017Inventors: Johannes Laurenz Kellenberger, Jürg Dreier
-
Patent number: 9738676Abstract: The application relates to the macrolide compound of the formula (I): wherein * indicates a stereocentre which is in (R) or (S) configuration, or a pharmaceutically acceptable salt or ester thereof and their use as PDE4 inhibitors.Type: GrantFiled: December 27, 2013Date of Patent: August 22, 2017Assignee: BASILEA PHARMACEUTICA AGInventors: Johannes Laurenz Kellenberger, Jürg Dreier
-
Publication number: 20150344515Abstract: The application relates to the macrolide compound of the formula (I): wherein * indicates a stereocentre which is in (R) or (S) configuration, or a pharmaceutically acceptable salt or ester thereof and their use as PDE4 inhibitors.Type: ApplicationFiled: December 27, 2013Publication date: December 3, 2015Inventors: Johannes Laurenz Kellenberger, Jürg Dreier
-
Patent number: 8933073Abstract: The invention relates to macrolide compounds of formula (I), the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with antiinflammatory activity mediated primarily through inhibition of phosphodiesterase 4 (PDE4) which makes them useful for the treatment and/or prevention of inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, atopic dermatitis or inflammatory bowel disease or proliferative diseases such as cancer.Type: GrantFiled: January 24, 2014Date of Patent: January 13, 2015Assignee: Basilea Pharmaceutica AGInventors: Johannes Laurenz Kellenberger, Jürg Dreier
-
Patent number: 8865662Abstract: The invention relates to macrolide compounds of formula (I), the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with antiinflammatory activity mediated primarily through inhibition of phosphodiesterase 4 (PDE4) which makes them useful for the treatment and/or prevention of inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, atopic dermatitis or inflammatory bowel disease or proliferative diseases such as cancer.Type: GrantFiled: August 13, 2010Date of Patent: October 21, 2014Assignee: Basilea Pharmaceutica AGInventors: Johannes Laurenz Kellenberger, Jürg Dreier
-
Publication number: 20140142100Abstract: The invention relates to macrolide compounds of formula (I), the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with antiinflammatory activity mediated primarily through inhibition of phosphodiesterase 4 (PDE4) which makes them useful for the treatment and/or prevention of inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, atopic dermatitis or inflammatory bowel disease or proliferative diseases such as cancer.Type: ApplicationFiled: January 24, 2014Publication date: May 22, 2014Applicant: BASILEA PHARMACEUTICA AGInventors: Johannes Laurenz Kellenberger, Jürg Dreier
-
Patent number: 8445451Abstract: Macrolides of Formula (I) or (I-A): and wherein the residues R1, R2, R3, R4, R12, R13 and R14 have certain meanings defined in this application are useful for treating or preventing inflammatory or allergic diseases or, cancer in animals and humans.Type: GrantFiled: February 9, 2009Date of Patent: May 21, 2013Assignee: Basilea Pharmaceutica AGInventors: Johannes Laurenz Kellenberger, Jürg Dreier, Stefan Bernhard Reinelt
-
Patent number: 8410065Abstract: The invention relates to antibiotic macrolides of formula (I), which have improved anti-inflammatory activity mediated through inhibition of phosphodiesterase 4 (PDE4) useful for the treatment and/or prevention of inflammatory, allergic and proliferative diseases.Type: GrantFiled: February 9, 2009Date of Patent: April 2, 2013Assignee: Basilea Pharmaceutica AGInventors: Johannes Laurenz Kellenberger, Jürg Dreier, Stefan Bernhard Reinelt
-
Publication number: 20120277174Abstract: The invention relates to macrolide compounds of formula (I), the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with antiinflammatory activity mediated primarily through inhibition of phosphodiesterase 4 (PDE4) which makes them useful for the treatment and/or prevention of inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, atopic dermatitis or inflammatory bowel disease or proliferative diseases such as cancer.Type: ApplicationFiled: August 13, 2010Publication date: November 1, 2012Applicant: BASILEA PHARMACEUTICA AGInventors: Johannes Laurenz Kellenberger, Jürg Dreier
-
Patent number: 8173609Abstract: New macrolide general compounds of formula I with improved activity making them useful for inhibiting human phosphodiesterase 4 and treating chronic obstructive pulmonary disease (COPD).Type: GrantFiled: August 8, 2007Date of Patent: May 8, 2012Assignee: Basilea Pharmaceutica AGInventors: Johannes Laurenz Kellenberger, Jürg Dreier, Stefan Bernhard Reinelt
-
Publication number: 20110053876Abstract: The invention relates to macrolide compounds of formula (I), the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with anti-inflammatory activity mediated primarily through inhibition of phosphodiesterase 4 (PDE4) which makes them useful for the treatment and/or prevention of inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, atopic dermatitis or inflammatory bowel disease or proliferative diseases such as cancer.Type: ApplicationFiled: February 9, 2009Publication date: March 3, 2011Inventors: Johannes Laurenz Kellenberger, Jürg Dreier, Stefan Bernhard Reinelt
-
Publication number: 20110021449Abstract: Macrolides of Formula (I) or (I-A): and wherein the residues R1, R2, R3, R4, R12, R13 and R14 have certain meanings defined in this application are useful for treating or preventing inflammatory or allergic diseases or. cancer in animals and humans.Type: ApplicationFiled: February 9, 2009Publication date: January 27, 2011Inventors: Johannes Laurenz Kellenberger, Jürg Dreier, Stefan Bernhard Reinelt
-
Publication number: 20100120706Abstract: Macrolide compounds of formula I: with PDF4 inhibiting activity are described, wherein R1 is a residue —Y—X-Q; Y is S, SO or SO2; X is a bond or a linear group consisting of hydrogen atoms and with up to 9 atoms selected from C, N, O and/or S, of which up to 2 atoms can be N and one atom can be O or S, one carbon atom can appear as a CO group and the sulphur atom can appear as an SO2 group and two adjacent C atoms can be present as —CH?CH— or —C?C— and which group X is unsubstituted or is substituted with —COO—W or —CONH—W; Q is a residue —V-A1-L-A2-W or, if X does not represent a bond, may also be —NR6R7; V is a divalent aromatic or heterocyclic group; W is aryl or heterocyclyl; or in a group —V-A1-L-A2-W, wherein at least one of the groups A1; L or A2 is present, can also be a monovalent substituted or unsubstituted, saturated or unsaturated linear group with up to 5 atoms consisting of C, N, O and/or S of which one carbon can appear as a CO group one sulphur atom can appear as an SO2 group, A1, A2 are indeType: ApplicationFiled: August 8, 2007Publication date: May 13, 2010Inventors: Johannes Laurenz Kellenberger, Jürg Dreier, Stefan Bernhard Reinelt
-
Patent number: 7524823Abstract: The present invention relates to new antibiotic macrolide compounds of the general formula I: with improved activity, to medicaments comprising such antibiotics, and to the use of such antibiotics for the treatment of infectious diseases, inflammatory diseases and human diseases or disorders which can be ameliorated by inhibition human phospdiesterases.Type: GrantFiled: May 8, 2006Date of Patent: April 28, 2009Assignee: Basilea Pharmaceutica AGInventors: Johannes Laurenz Kellenberger, Stuart Robert Shapiro, Salima Mathews, Philippe Guerry, Pierre Jacques Noël Barbier
-
Patent number: 6995143Abstract: The invention provides new macrolides antibiotics of formula I with improved biological properties and having the formula wherein R1, R2 and R3 are as herein described.Type: GrantFiled: February 20, 2003Date of Patent: February 7, 2006Assignee: Basilea Pharmaceutica AGInventors: Philippe Guerry, Johannes Laurenz Kellenberger, Stéphanie Blanchard
-
Publication number: 20030212011Abstract: The invention provides new macrolides antibiotics of formula I with improved biological properties and having the formula 1Type: ApplicationFiled: February 20, 2003Publication date: November 13, 2003Inventors: Philippe Guerry, Johannes Laurenz Kellenberger